Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 13/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | BRD2 | P25440 | 2/20 | 0.42 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12106068 | 0.88 | FAAH (0.58) | FAAHPTGS2PTGS1KCNH2 | |
| SCHEMBL12106019 | 0.83 | FAAH (0.62) | FAAHPTGS2PTGS1KCNH2 | |
| SCHEMBL12106262 | 0.82 | FAAH (0.58) | FAAHPTGS2PTGS1KCNH2 | |
| SCHEMBL1302731 | 0.82 | FAAH (0.53) | FAAHPTGS2PTGS1KCNH2 | |
| SCHEMBL1303953 | 0.81 | FAAH (0.55) | FAAHPTGS2PTGS1KCNH2 | |
| SCHEMBL8005584 | 0.81 | FAAH (0.52) | FAAHPTGS2PTGS1KCNH2 | |
| SCHEMBL12106256 | 0.80 | FAAH (0.64) | FAAHPTGS2PTGS1KCNH2 | |
| SCHEMBL12106051 | 0.80 | FAAH (0.54) | FAAHPTGS2PTGS1KCNH2 | |
| SCHEMBL12106327 | 0.79 | FAAH (0.79) | FAAHPTGS2PTGS1KCNH2 | |
| SCHEMBL12106873 | 0.78 | FAAH (0.54) | FAAHPTGS2PTGS1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455528-B2 | Imidazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455528-B2 | Imidazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110269769-A1 | IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-11-03 | — | — | US | disclosed |
| US-20110269769-A1 | IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-11-03 | — | — | US | disclosed |
| WO-2009152025-A1 | IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK & CO., INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269769-A1 | IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, HNMT | FAAH 1/4885PTGS2 41/4885PTGS1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.